Standout Papers

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in ... 2005 2026 2012 2019 1.1k
  1. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. (2005)
    Michel Marty, Francesco Cognetti et al. IRIS UNIMORE (University of Modena and Reggio Emilia)

Immediate Impact

8 by Nobel laureates 15 from Science/Nature 72 standout
Sub-graph 1 of 19

Citing Papers

Translating p53-based therapies for cancer into the clinic
2024 Standout
N6-methyladenosine regulated FGFR4 attenuates ferroptotic cell death in recalcitrant HER2-positive breast cancer
2022 Standout
8 intermediate papers

Works of Michel Marty being referenced

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.
2005 Standout
Effect of mutated TP53 on response of advanced breast cancers to high-dose chemotherapy
2002

Author Peers

Author Last Decade Papers Cites
Michel Marty 564 1806 243 734 611 47 3.0k
D C Tormey 381 2085 569 1110 288 54 3.5k
Wilson J. Angerson 1187 1998 114 621 548 85 4.0k
Alexander Paterson 694 3907 307 817 1460 102 4.9k
Maccon Keane 219 1527 193 913 514 73 3.4k
Roger Keresztes 330 1078 200 451 191 36 2.6k
Mary Cabiddu 851 2427 454 757 215 77 3.7k
Jeroen T. Buijs 227 1432 98 500 278 51 2.8k
Peter Vermeulen 383 2257 310 1244 299 76 3.9k
Giannoula Klement 666 1677 244 1168 231 67 4.8k
Petr Kavan 376 1413 459 851 402 137 4.2k

All Works

Loading papers...

Rankless by CCL
2026